Journal of Shanghai Jiao Tong University (Medical Science) >
Cell-penetrating peptide Penetratin-modified liposomes for ophthalmic application: construction and in vitro evaluation
Online published: 2021-05-27
Supported by
Key Science and Technology Program of Songjiang District(18sjkjgg);Jiaxing Key Laboratory of Oncological Photodynamic Therapy and Targeted Drug Research
·To prepare the cell-penetrating peptide Penetratin-modified liposome (Pen-Lip) for ophthalmic application and evaluate its applicability to treat fundus neovascularization diseases through topical instillation.
·The copolymer DSPE-PEG2000-Pen was synthesized by the addition reaction of DSPE-PEG2000-Mal and Penetratin, and Pen-Lip was then prepared by the thin film dispersion method. The cellular uptake experiment was used to determine the optimal ratio of Penetratin to modify liposomes. The average particle size, Zeta potential and polydispersity index (PDI) of Pen-Lip were characterized by the nano particle size potentiometer, and the morphology of Pen-Lip was observed by using transmission electron microscope (TEM). The encapsulation efficiency and the drug loading of Pen-Lip with conbercept were determined by centrifugation. Pen-lip was incubated in the PBS or the PBS containing 50% fetal bovine serum for 48 h and the stability of Pen-Lip was investigated by the change of particle size and the morphology under TEM. The CCK-8 assay was conducted to detect the cytotoxicity of Pen-Lip to human corneal epithelial cell (HCEC) and human retinal pigment epithelium (ARPE-19), and the uptake of Pen-Lip by ARPE-19 was observed by using laser confocal microscope. The diffusion cell device was used to detect the permeability of Pen-Lip through the isolated rabbit cornea, and the apparent permeability coefficient (Papp) was calculated. The toxicity of Pen-Lip with conbercept to the corneal tissue was evaluated by the hydration value.
·The optimal ratio of Penetratin to modify liposomes was 3%. The average particle size of Pen-Lip was (148.07±3.51) nm, the Zeta potential was (5.66±0.91) mV, and the PDI was 0.227±0.045. TEM results showed that Pen-Lip had a smooth spherical structure. The encapsulation efficiency of Pen-Lip was (44.06±3.70) %, and the drug loading was (2.84±0.24) %. The particle size of Pen-Lip did not change significantly and TEM showed uniform dispersion after dispersing in the PBS or the PBS containing 50% fetal bovine serum for 48 h, exhibiting the good stability of Pen-Lip. When Pen-Lip was at the concentration of 15?500 μg/mL, Pen-Lip had no cytotoxicity to HCEC and ARPE-19. Compared with unmodified liposomes, ARPE-19 cells had significantly higher uptake of Pen-Lip (P=0.000). In the experiment of rabbit cornea penetration in vitro, the Papp of Pen-Lip was significantly higher than that of unmodified liposomes (P=0.000). There was no statistically significant difference in the hydration value of the rabbit cornea treated with drug-loaded Pen-Lip compared to the untreatd group (P>0.05).
·Pen-Lip has good stability, biocompatibility and corneal permeability in vitro and can be taken up by retinal cells, which is a potential ocular drug delivery system to treat fundus neovascularization diseases through topical instillation.
Nan XU , Shu-yue ZHANG , Xue-ying DING . Cell-penetrating peptide Penetratin-modified liposomes for ophthalmic application: construction and in vitro evaluation[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2021 , 41(5) : 595 -602 . DOI: 10.3969/j.issn.1674-8115.2021.05.006
1 | Campochiaro PA. Ocular neovascularization[J]. J Mol Med (Berl), 2013, 91(3): 311-321. |
2 | Li X, Xu G, Wang Y, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration. Results from a 12-month randomized phase 2 study: AURORA study[J]. Ophthalmology, 2014, 121(9): 1740-1747. |
3 | Sivaprasad S, Prevost AT, Vasconcelos JC, et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial[J]. Lancet, 2017, 389(10085): 2193-2203. |
4 | Sisk RA, Patel YP, Foster RE, et al. Erosive retinopathy and retinal detachment from depot intravitreal triamcinolone acetonide injection at the end of pars plana vitrectomy[J]. Ophthalmic Surg Lasers Imaging Retin, 2019, 50(10): 613-619. |
5 | Gross JG, Glassman AR, Jampol LM, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial[J]. JAMA, 2015, 314(20): 2137-2146. |
6 | Chen C, Liu K, Xu Y, et al. Anti-angiogenesis through noninvasive to minimally invasive intraocular delivery of the peptide CC12 identified by in vivo-directed evolution[J]. Biomaterials, 2017, 112: 218-233. |
7 | Li J, Cheng T, Tian Q, et al. A more efficient ocular delivery system of triamcinolone acetonide as eye drop to the posterior segment of the eye[J]. Drug Deliv, 2019, 26(1): 188-198. |
8 | Jiang K, Hu Y, Gao X, et al. Octopus-like flexible vector for noninvasive intraocular delivery of short interfering nucleic acids[J]. Nano Lett, 2019, 19(9): 6410-6417. |
9 | Yang X, Wang L, Li L, et al. A novel dendrimer-based complex co-modified with cyclic RGD hexapeptide and penetratin for noninvasive targeting and penetration of the ocular posterior segment[J]. Drug Deliv, 2019, 26(1): 989-1001. |
10 | Dos Santos Rodrigues B, Kanekiyo T, Singh J. ApoE-2 brain-targeted gene therapy through transferrin and penetratin tagged liposomal nanoparticles[J]. Pharm Res, 2019, 36(11): 161. |
11 | Shuai Q, Cai Y, Zhao G, et al. Cell-penetrating peptide modified PEG-PLA micelles for efficient PTX delivery[J]. Int J Mol Sci, 2020, 21(5): 1856. |
12 | de Cogan F, Hill LJ, Lynch A, et al. Topical delivery of anti-VEGF drugs to the ocular posterior segment using cell-penetrating peptides[J]. Invest Ophthalmol Vis Sci, 2017, 58(5): 2578-2590. |
13 | Liu C, Tai LY, Zhang WJ, et al. Penetratin, a potentially powerful absorption enhancer for noninvasive intraocular drug delivery[J]. Mol Pharm, 2014, 11(4): 1218-1227. |
14 | Cheng T, Li J, Cheng Y, et al. Triamcinolone acetonide-chitosan coated liposomes efficiently treated retinal edema as eye drops[J]. Exp Eye Res, 2019, 188: 107805. |
15 | Lai S, Wei Y, Wu Q, et al. Liposomes for effective drug delivery to the ocular posterior chamber[J]. J Nanobiotechnology, 2019, 17(1): 64. |
16 | Zhang Q, Tang J, Fu L, et al. A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system[J]. Biomaterials, 2013, 34(32): 7980-7993. |
17 | Liu Y, Lu Z, Mei L, et al. Tandem peptide based on structural modification of poly-arginine for enhancing tumor targeting efficiency and therapeutic effect[J]. ACS Appl Mater Interfaces, 2017, 9(3): 2083-2092. |
18 | Tai LY, Liu C, Jiang K, et al. A novel penetratin-modified complex for noninvasive intraocular delivery of antisense oligonucleotides[J]. Int J Pharm, 2017, 529(1/2): 347-356. |
19 | Eriksen AZ, Brewer J, Andresen TL, et al. The diffusion dynamics of PEGylated liposomes in the intact vitreous of the ex vivo porcine eye: a fluorescence correlation spectroscopy and biodistribution study[J]. Int J Pharm, 2017, 522(1-2): 90-97. |
20 | Garbuzenko O, Barenholz Y, Priev A. Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer[J]. Chem Phys Lipids, 2005, 135(2): 117-129. |
21 | Davis BM, Normando EM, Guo L, et al. Topical delivery of avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes[J]. Small, 2014, 10(8): 1575-1584. |
/
〈 |
|
〉 |